SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
SAB BIO received FDA Fast Track designation for SAB-142, its lead immunotherapy for new-onset Stage 3 type 1 diabetes. The designation facilitates development and expedites FDA review of therapies addressing serious unmet medical needs, and reflects the agency's view that SAB-142 could be disease-modifying.
Key figures
- Drug Name
- SAB-142
- Phase Of Trial
- Phase 2b
- Designations
- FDA Fast Track
- Topline data
- 2H 2027
- Enrollment completion
- Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.